Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Says NDA for GIST Precision Medicine Accepted for Review in China

publication date: Apr 23, 2020

CStone Pharma of Suzhou announced that China's NMPA has accepted its NDA of avapritinib, a precision therapy aimed at treating GIST. Avapritinib is an investigational, orally available inhibitor of KIT and PDGFRA mutant kinases. In 2018, CStone in-licensed China rights to avapritinib from Blueprint Medicines in a $386 million deal, and Blueprint was approved for a US launch of the drug in January. In 2015, CStone was founded with $150 million in capital from Oriza, Boyu and 6 Dimensions. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.